title: Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
abstract: BACKGROUND
  This single-centre retrospective analysis of data from three randomised studies and two expanded-access studies compared the effect of interferon (IFN)-alfa, sunitinib, and sorafenib on the occurrence and progression of metastatic bone lesions in patients with renal cell carcinoma (RCC).
  
  
  METHODS
  The analysis included 292 patients: 107 received sunitinib 50 mg/day in 6-week cycles (Schedule 4/2), 147 received sorafenib 800 mg/day, and 38 received placebo or IFN-alfa 9 MU t.i.w.
  
  
  RESULTS
  Pre-existing metastatic bone lesions were reported in 82 patients, of which 30 experienced progression. Twenty-three of 210 patients developed new bone lesions. Overall, sunitinib appeared slightly more effective than sorafenib or IFN-alfa at extending mean time to progression of pre-existing bone lesions (P = 0.057). Compared with sorafenib, sunitinib significantly decreased formation (P = 0.034) and prolonged time to occurrence of new bone lesions (P = 0.047).
  
  
  CONCLUSIONS
  Further evaluation of the effect of these therapies on bone metastases in RCC is warranted.
authors.affiliation: Oncology Clinic, CSK MON WIM, Warsaw, Poland. qbazolnier@wp.pl
authors.forename: Jakub
authors.initials: J
authors.lastname: Zołnierek
authors.forename: Pawel
authors.initials: P
authors.lastname: Nurzyński
authors.forename: Przemysław
authors.initials: P
authors.lastname: Langiewicz
authors.forename: Sylwia
authors.initials: S
authors.lastname: Oborska
authors.forename: Anna
authors.initials: A
authors.lastname: Waśko-Grabowska
authors.forename: Ewa
authors.initials: E
authors.lastname: Kuszatal
authors.forename: Beata
authors.initials: B
authors.lastname: Obrocka
authors.forename: Cezary
authors.initials: C
authors.lastname: Szczylik
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D057176:Compassionate Use Trials; D018450:Disease Progression; D016503:Drug Delivery Systems / Q000379:methods; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D016898:Interferon-alpha / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010919:Placebos; D011725:Pyridines / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D000077157:Sorafenib; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D001557:Benzenesulfonates; D007211:Indoles; D016898:Interferon-alpha; D010671:Phenylurea Compounds; D010919:Placebos; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib